Status:
COMPLETED
Efficacy and Safety of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis
Lead Sponsor:
Jennifer Keiser
Collaborating Sponsors:
National Centre for Parasitology, Entomology and Malaria Control, Cambodia
Conditions:
Strongyloides Stercoralis Infection
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The study is an extension to the study StrongMoxi NCT04056325 and entails modifications based on the outcome of NCT04056325 part A. The study is a phase 3, double-blinded and randomized clinical tria...
Detailed Description
The study is a phase 3 trial and will determine the efficacy and safety of: 8 mg of moxidectin in comparison to the standard treatment dose of ivermectin (200 μg/kg) in adults infected with S. sterco...
Eligibility Criteria
Inclusion
- Adults (18-65 years)
- Infected with S. stercoralis (positive)
- Absence of major systemic illnesses
- Written informed consent
Exclusion
- Any abnormal medical conditions or chronic disease
- Negative diagnostic result for S. stercoralis
- No written informed consent by the individual.
- Pregnant and lactating women.
- Recent use of an anthelmintic drug (within past 4 weeks)
- Attending other clinical trials during the study
- Known allergy to study medications (i.e. moxidectin, ivermectin)
- Currently taking medications with known interaction (i.e. for warfarin)
Key Trial Info
Start Date :
February 5 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 17 2022
Estimated Enrollment :
332 Patients enrolled
Trial Details
Trial ID
NCT04848688
Start Date
February 5 2022
End Date
July 17 2022
Last Update
January 25 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Centre for Parasitology, Entomology and Malaria Control
Phnom Penh, Cambodia